Literature DB >> 22514428

HIV-related non-Hodgkin's lymphoma in Calgary.

P L Beck1, M J Gill, W B Blahey, L R Sutherland.   

Abstract

OBJECTIVE: To determine the incidence of human immunodeficiency virus (HIV) associated non-Hodgkin's lymphoma (NHL) in a cohort of patients from a distinct geographic region (southern Alberta). The type and location of NHL as well as how it affected the survival of these patients was examined. PATIENTS AND METHODS: The Southern Alberta HIV Clinic in Calgary serves all of southern Alberta, which has an estimated population of one million. The clinic has provided primary care for 1086 patients from January 1983 to August 1995. Data were obtained by reviewing the clinic's database and patients' charts.
RESULTS: Over a 12-year period, 39 cases of NHL were diagnosed in a group of 1086 HIV-infected patients. Presentation of NHL was at an extranodal site in all but four cases, with the most common sites being the bowel and central nervous system. The mean CD4 count on presentation with NHL was 143.4±37.4×10(6)/L (range 1 to 1219×10(6)/L). Mean survival was 1.25±0.25 years with a range from 0 (diagnosed on autopsy) to 6.45 years. Patients with a CD4 count of less than 200×10(6)/L and/or diagnosed with an AIDS-defining illness before development of NHL had significantly reduced survival (0.85 years versus 2.48 years, P<0.02 and 0.57 years versus 2.09 years, P<0.001, respectively). Patients who presented with NHL involving either nodes alone or central nervous system had significantly decreased survival (0.28 years and 0.29 years, respectively, P<0.05). Patients with NHL involving the gastrointestinal tract had a longer mean survival than those with NHL elsewhere (P<0.05). All but seven cases received therapy for NHL including chemotherapy, radiotherapy, surgery or combined therapy. Fifteen patients (47% of treated) achieved a complete response that led to improved survival (P<0.01). Patients tolerated surgery, chemotherapy and radiotherapy well and no deaths were due to NHL therapy.
CONCLUSIONS: These data suggest that development of NHL in HIV is associated with reduced survival, and that survival is predominantly determined by CD4 count and site of involvement at the time of diagnosis of NHL.

Entities:  

Keywords:  Human immunodeficiency virus; Non-Hodgkin’s lymphoma

Year:  1996        PMID: 22514428      PMCID: PMC3327386          DOI: 10.1155/1996/748584

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  27 in total

Review 1.  The expanding challenge of HIV-associated malignancies.

Authors:  S Broder; J E Karp
Journal:  CA Cancer J Clin       Date:  1992 Mar-Apr       Impact factor: 508.702

Review 2.  Malignant neoplasms associated with human immunodeficiency virus infection.

Authors:  B Safai; B Diaz; J Schwartz
Journal:  CA Cancer J Clin       Date:  1992 Mar-Apr       Impact factor: 508.702

3.  HIV-related malignant lymphoma: clinical aspects, treatment, and pathogenesis.

Authors:  P S Gill; A M Levine
Journal:  Cancer Invest       Date:  1988       Impact factor: 2.176

Review 4.  HIV-associated Hodgkin disease: a clinical study of 18 cases and review of the literature.

Authors:  J E Gold; D Altarac; H J Ree; A Khan; P P Sordillo; R Zalusky
Journal:  Am J Hematol       Date:  1991-02       Impact factor: 10.047

5.  Post-transplant malignant lymphoma. Distinctive morphologic features related to its pathogenesis.

Authors:  A J Matas; B F Hertel; J Rosai; R L Simmoms; J S Najarian
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

6.  Clinical and epidemiological implications of the Centers for Disease Control/World Health Organization reclassification of AIDS cases.

Authors:  R P Brettle; S M Gore; A G Bird; A J McNeil
Journal:  AIDS       Date:  1993-04       Impact factor: 4.177

7.  The role of initial AIDS-defining illness in survival following AIDS.

Authors:  K Luo; M Law; J M Kaldor; A M McDonald; D A Cooper
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

8.  Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia.

Authors:  C S Rabkin; M W Hilgartner; K W Hedberg; L M Aledort; A Hatzakis; S Eichinger; M E Eyster; G C White; C M Kessler; M M Lederman
Journal:  JAMA       Date:  1992-02-26       Impact factor: 56.272

9.  Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy.

Authors:  J M Pluda; R Yarchoan; E S Jaffe; I M Feuerstein; D Solomon; S M Steinberg; K M Wyvill; A Raubitschek; D Katz; S Broder
Journal:  Ann Intern Med       Date:  1990-08-15       Impact factor: 25.391

10.  Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.

Authors:  P J Easterbrook; J Emami; B Gazzard
Journal:  AIDS       Date:  1993-10       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.